CLINICAL TRIAL
CONTROLLED CLINICAL TRIAL
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Antibodies to 125I-glutamic acid decarboxylase in patients with stiff man syndrome.
Antibodies to glutamic acid decarboxylase (GAD) are found in about 40% of patients with stiff man syndrome. A new assay involving immunoprecipitation of (125)I-glutamic acid decarboxylase was used to measure anti-GAD antibodies in 18 patients with stiff man syndrome. Of the eight serum samples from patients with stiff man syndrome, that had previously been found positive by immunoprecipitation of (35)S-GAD, seven were strongly positive with (125)I-GAD and one gave an equivocal result. Other serum samples from patients with stiff man syndrome and from controls were negative except one from a patient who had a thymoma, acquired neuromyotonia, and myasthenia gravis. Nine of 35 serum samples referred for testing were positive; in two of these the serum titre was 20-50 times higher than that in the CSF. This assay should prove useful in the diagnosis, management, and investigation of stiff man syndrome.
Full text links
Trending Papers
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis.Nature Reviews. Rheumatology 2023 May 10
A Systematic Approach to Understanding Acid-Base Disorders in the Critically Ill.Annals of Pharmacotherapy 2023 April 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app